Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) shares were down 0.3% during trading on Thursday . The company traded as low as C$7.25 and last traded at C$7.45. Approximately 94,575 shares were traded during trading, an increase of 1,176% from the average daily volume of 7,410 shares. The stock had previously closed at C$7.47.
Eupraxia Pharmaceuticals Stock Performance
The company’s fifty day moving average price is C$7.32 and its two-hundred day moving average price is C$7.26.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
Further Reading
- Five stocks we like better than Eupraxia Pharmaceuticals
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
